Are you Dr. Gartner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
Karmanos Cancer Center
4100 John R Hwcrc 4th Fl
Detroit, MI 48201Phone+1 800-527-6266
Summary
- Dr. Elaina Gartner, MD is an oncologist in Detroit, Michigan. She is currently licensed to practice medicine in Michigan. She is affiliated with DMC Harper University Hospital and DMC Detroit Receiving Hospital & University Health Center.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 1999 - 2002
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1996 - 1999
Washington University in St. Louis School of MedicineClass of 1996
Certifications & Licensure
MI State Medical License 1999 - 2025
Clinical Trials
- Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2005 Sep 01
- Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen Start of enrollment: 2005 May 01
- Safety Study of SGN-CD70A in Cancer Patients Start of enrollment: 2014 Aug 01
Publications & Presentations
PubMed
- 49 citationsPhase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast ca...Sara M. Tolaney, Howard A. Burris, Elaina M. Gartner, Ingrid A. Mayer, Cristina Saura
Breast Cancer Research and Treatment. 2015-01-01 - 162 citationsEV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David Smith, D. Ruether
Journal of Clinical Oncology. 2020-02-07 - 362 citationsPivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.Jonathan E. Rosenberg, Peter H. O'Donnell, Arjun Vasant Balar, Bradley Alexander McGregor, Elisabeth I. Heath
Journal of Clinical Oncology. 2019-07-29
Professional Memberships
- Member
